Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective

• Main Authors: Tan, P.-T, Aziz, M.I.A, Pearce, F, Lim, W.-T, Wu, D.B.-C, Ng, K
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: afatinib; cisplatin; epidermal growth factor receptor; pemetrexed; antineoplastic agent; advanced cancer; Article; cancer chemotherapy; cancer growth; comparative effectiveness; controlled study; cost effectiveness analysis; death; drug cost; drug effect; drug efficacy; drug response; drug safety; EGFR gene; gene mutation; human; major clinical study; medical decision making; multiple cycle treatment; non small cell lung cancer; overall survival; phase 3 clinical trial; progression free survival; quality of life; randomized controlled trial; sensitivity analysis; Singapore; survival rate; treatment outcome; cancer staging; clinical trial; cost benefit analysis; genetics; health care cost; lung tumor; metastasis; mortality; mutation; pathology; prognosis; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; ErbB Receptors; Health Care Costs; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Prognosis; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181206
• Institution: National University of Singapore

10.1186/s12885-018-4223-y